Biotech and Bristol-Myers Squibb published positive global phase 2 data from Pumitamig in advanced non-small cell lung cancer progressing after immunotherapy combined with chemotherapy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.